ReShape Lifesciences, Inc. (RSLS): Enterprise Value to EBITDA Ratio
ReShape Lifesciences (RSLS) aims to expand B2B distribution of Lap-Band systems, yet liquidity shortages and asset restructuring following the merger with a biopharma entity create risks for operational stability. This price chart reflects the EV/EBITDA dynamics, which currently stands at . While the business relies on minimally invasive weight loss methods, it faces significant pressure due to the popularity of modern injectable drugs.
Comprehensive metric breakdowns and analytics for reshapelifesciences.com (RSLS)
- stock price and consensus target price:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio ReShape Lifesciences|RSLS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ReShape Lifesciences Inc.|RSLS - Company Total Debt|Debts to Book Capitalization ReShape Lifesciences|RSLS - Long-Term Debt|Company Short-Term Debts ReShape Lifesciences|Quick Ratio reshapelifesciences.com
- financial results and valuation multiples details:
RSLS - Net Financial Result|Projected Future Earnings ReShape Lifesciences|RSLS - Price to Earnings Ratio|Forward P/E Multiple ReShape Lifesciences Inc.|RSLS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ReShape Lifesciences|RSLS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months ReShape Lifesciences|RSLS - Earnings per share for the trailing year|Quarterly EPS earnings growth reshapelifesciences.com|RSLS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year ReShape Lifesciences
Analysis of all company metrics:ReShape Lifesciences Inc RSLS
The EV/EBITDA multiple determines the business value inclusive of net debt relative to operating profit, allowing for an assessment of the asset's real value without the influence of the tax regime. For ReShape Lifesciences (RSLS), which is restructuring its surgical segment under pressure from GLP-1 drugs, the company's EV/EBITDA valuation trend serves as an indicator of debt sustainability. Analyzing this chart helps determine whether the capital is overvalued amid a shifting market paradigm.
Competitor analysis
Dexcom Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Penumbra Medical PEN|NOVT: Enterprise Value to EBITDA Ratio|haemonetics.com - Enterprise Value to Operating Income Before Depreciation Ratio|INSP: EV/EBITDA Multiple|PRCT - Total Company Value to Operating Income Before Depreciation Ratio|CNMD (CONMED Corp.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulse Medical (PLSE)|Enterprise Value to EBITDA Ratio INMD (InMode Ltd.)|PMI (picardmedical.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Surmodics SRDX|SENS - Enterprise Value to EBITDA Ratio|NeuroPace Corp - EV/EBITDA Multiple|Company Value to EBITDA Tactile Systems Technology|SNWV: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation OM|ELMD (SmartVest) - EV/EBITDA Multiple|LENSAR Inc. (LNSR) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCEL|Enterprise Value to EBITDA Ratio profoundmedical.com PROF|EV/EBITDA Multiple BDMD (Baird Medical)|EV/EBITDA Multiple EDAP TMS SA EDAP|APYX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ICCM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LUNG (pulmonx.com) - Enterprise Value to EBITDA Ratio|TELA Bio - Business Value to Operating Income Before Depreciation|CTSO (CytoSorbents Corp) - EV/EBITDA Multiple|Company Value to EBITDA sensushealthcare.com SRTS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zynex (ZYXI)|electrocore.com (ECOR) - Enterprise Value to EBITDA Multiple|Vicarious Surgical - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Inspira Technologies Oxy B.H.N. Ltd. IINN|SeaStar Medical Holding - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio IRIDEX Corporation IRIX|ibs.inc (INBS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XAIR (Beyond Air)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Profusa, Inc.|Enterprise Value to EBITDA Ratio STRATA Skin (SSKN)|EV/EBITDA Multiple GCTK|NAOV - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Venus Concept VERO|NUWE: Enterprise Value to Operating Income Before Depreciation|AEMD: Enterprise Value to EBITDA Ratio|Asensus Surgical, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|Avinger, Inc. (AVGR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BioSig Technologies Inc. - Business Value to Operating Income Before Depreciation|CUTR (Cutera) - EV/EBITDA Multiple|Company Value to EBITDA Know Labs Inc KNW|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inari (NARI)|Total Company Value to Operating Income Before Depreciation Ratio Nevro Medical|EV/EBITDA Multiple SILK (Silk Road Medical, Inc)
